In addition, monoclonal anti-VEGF antibody (Avastin or Bevacizumab) is the first anti-angiogenic drug that is known for its ability to inhibit tumor blood vessel growth as well as its ability to increase survival rate in cancer patients [11,12]. This evidence concerns the gene VEGFA and cancer.